Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) can cause severe, persistent neurological deficits and disability. Currently, there is a need for efficacious and safe therapies for long-term relapse prevention. Kazuo Fujihara, MD, PhD, Fukushima Medical University School of Medicine, Fukishima, Japan, outlines the details of the Phase III, randomized, double-blind, placebo-controlled METEOROID (NCT05271409) study evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of satralizumab as monotherapy or in addition to background immunosuppressive therapy in patients with relapsing MOGAD. The primary endpoint is time to first MOGAD relapse in the double-blind period. Patient enrolment has started, and results are awaited as this is the first study of satralizumab in MOGAD. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.